CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CRISPR Therapeutics AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$50.04+0.79 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $4.83B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$19.11 (−27.64%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CRISPR Therapeutics AG saw revenue fall 64.8% to $13.39M over the twelve months to Jun 30, 2026. Free cash flow was -$371.33M.
Revenue
$13.39M
-64.8% vs. a year earlier
Operating income
-$534.34M
TTM Q2 2026
Free cash flow
-$371.33M
TTM Q2 2026
EPS, diluted
-$4.76
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.83B
- P/E ratio
- –
- Price to sales
- 360.63
- Price to book
- 2.77
- Dividend yield
- –
- Free cash flow yield
- -7.69%
Fundamentals
- Revenue
- $13.39M
- Net income
- -$451.14M
- EPS, diluted
- -$4.76
- Free cash flow
- -$371.33M
- Book value per share
- $18.10
- Diluted shares
- 97M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$13.39M-64.8% YoY
Operating income
-$534.34M
Net income
-$451.14M
EPS, diluted
-$4.76
Free cash flow
-$371.33M
Reported periodTrailing twelve months